Literature DB >> 8508597

Mammography in the assessment of response to medical treatment of large primary breast cancer.

E C Moskovic1, J L Mansi, D M King, C R Murch, I E Smith.   

Abstract

The sequential mammograms of 48 patients (median age: 54 years, range: 24-84 years) undergoing primary medical treatment for large operable breast cancer at this institution were reviewed, and compared to the findings at clinical assessment. Twenty-six patients underwent endocrine therapy using tamoxifen, and 22 chemotherapy (CMF or MMM). All had more than two mammograms which were reviewed blindly by two independent radiologists. Response to treatment by both evaluation modalities was recorded using WHO definitions (NC, PR, CR, PD). Some 81% of patients achieved an objective clinical response to treatment, whilst 63% showed mammographic response. Overall comparison of clinical examination with mammography showed agreement in 38 patients (79%) and disagreement in 10 (21%). Agreement in type of response but not in its degree was found in 22 cases (46%). The results suggest that in the majority of cases mammography provides a useful adjunct to clinical examination in monitoring response to primary medical treatment for breast cancer. However, radiological factors such as unchanging microcalcification, and the continuing presence of mammographic density contribute to the discrepancy with clinical response in some tumours, and the search for alternative modalities of assessment should continue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508597     DOI: 10.1016/s0009-9260(05)81451-5

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  17 in total

1.  Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy.

Authors:  H J Shin; H H Kim; J H Ahn; S-B Kim; K H Jung; G Gong; B H Son; S H Ahn
Journal:  Br J Radiol       Date:  2010-11-16       Impact factor: 3.039

2.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.

Authors:  Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft
Journal:  Am J Surg       Date:  2010-04       Impact factor: 2.565

3.  Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?

Authors:  Yara Feliciano; Anita Mamtani; Monica Morrow; Michelle M Stempel; Sujata Patil; Maxine S Jochelson
Journal:  Ann Surg Oncol       Date:  2017-01-05       Impact factor: 5.344

4.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.

Authors:  Viviana Londero; Massimo Bazzocchi; Chiara Del Frate; Fabio Puglisi; Carla Di Loreto; Giuliana Francescutti; Chiara Zuiani
Journal:  Eur Radiol       Date:  2004-02-18       Impact factor: 5.315

5.  Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature.

Authors:  Sommer R Gunia; Mita S Patel; Eleftherios P Mamounas
Journal:  Case Rep Surg       Date:  2012-01-19

Review 6.  Monitoring therapeutic efficacy in breast carcinomas.

Authors:  Anne A Tardivon; Liliane Ollivier; Carl El Khoury; Fabienne Thibault
Journal:  Eur Radiol       Date:  2006-05-30       Impact factor: 7.034

7.  Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

Authors:  M T Seymour; E C Moskovic; G Walsh; P Trott; I E Smith
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Imaging in evaluation of response to neoadjuvant breast cancer treatment.

Authors:  L Ollivier; C Balu-Maestro; J Leclère
Journal:  Cancer Imaging       Date:  2005-05-24       Impact factor: 3.909

9.  Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

Authors:  E van der Wall; E J Rutgers; M J Holtkamp; J W Baars; J H Schornagel; J L Peterse; J H Beijnen; S Rodenhuis
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

10.  The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation.

Authors:  Jun-jie Li; Canming Chen; Yajia Gu; Genhong Di; Jiong Wu; Guangyu Liu; ZhiMin Shao
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.